MAP2K5 and neoplasm: Consistently, newer data using specific kinase inhibitors for the MEK5/ERK5 pathway, as well as siRNA depletion experiments, demonstrated that tumor cells with oncogenic KRAS or BRAF mutations or ERK5 amplification were not addicted to ERK5 activity for proliferation [36].